Cinnarizine是一种口服有效且高选择性的L型钙通道Cav1.3抑制剂。Cinnarizine能够透过血脑屏障，调节钙稳态及多巴胺神经传递。通过阻断L型钙通道抑制钙离子内流，桂利嗪可舒张血管平滑肌、改善脑循环并降低血液黏度，同时具有多巴胺受体拮抗作用。该药物适用于前庭性眩晕、梅尼埃病及脑血管疾病的相关研究。
| 英文别名 (English Synonym) | Cinnarizine |
| 中文名称 (Chinese Name) | 桂利嗪 |
| 靶点 (Target) | Histamine Receptor |
| 通路 (Pathway) | Neuroscience |
| CAS号 (CAS NO.) | 298-57-7 |
| 分子式 (Formula) | C26H28N2 |
| 分子量 (Molecular Weight) | 368.51 |
| 纯度 (Purity) | ≥98% |
| 溶解性 (Solubility) | 溶于DMSO |
-25~-15℃保存，有效期3年
[1] Arab SF, Düwel P, Jüngling E, Westhofen M, Lückhoff A. Inhibition of voltage-gated calcium currents in type II vestibular hair cells by cinnarizine. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):570-5. doi: 10.1007/s00210-004-0936-3. Epub 2004 May 11. PMID: 15138660.
[2] Serrano A, Menéndez J, Casarejos MJ, Solano RM, Gallego E, Sánchez M, Mena MA, García de Yebenes J. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology. 2005 Aug;49(2):208-19. doi: 10.1016/j.neuropharm.2005.03.003. PMID: 15993444.
